All posts from TipRanks
TipRanks in TipRanks,

Wednesday’s Top Upgrades and Downgrades: LinkedIn Corp (LNKD), SanDisk Corporation (SNDK), Zions Bancorporation (ZION), WebMD Health Corp. (WBMD)

There has been a lot of action on Wall Street today as analysts have weighed in on their favorite stocks. Below are the most notable analyst upgrades and downgrades:

LinkedIn Corp

Sarah Hindlian of Brean Capital upgraded her rating on LinkedIn Corp (NYSE:LNKD) from Sell to Hold as she views “the risk-reward as more balanced at this time.” Several of the analyst’s previous “concerns have largely played out, and note that Sales Navigator has been a disappointment and potentially cannibalized other premium subscriptions per [her] initial concerns on use case/price, while Talent Solutions growth has notably slowed with heavy penetration of price insensitive large enterprises.” However, “after several quarters of significant sell-offs, with the stock declining ~30% since its well-received Q4’14 earnings report, reduced FY’15 guidance ex-lynda, somewhat reset investor expectations, lessening headwinds to Marketing Solutions from secular shifts in advertising, as well as guidance and valuation more accurately incorporating slower growth, [she is] moving to the sidelines with our Hold rating.”

Click here to view Sarah Hindlian’s rating history and performance.

SanDisk Corporation

Goldman Sachs analyst Mark Delaney downgraded his rating on SanDisk Corporation (NASDAQ:SNDK) from Buy to Neutral and slashed his price target from $73 to $55, representing a 0.59% potential downside from where the stock last closed. According to thefly.com, the analyst reasoned his downgrade on his belief that increasing output and weaker smartphone sales will lead to lower NAND selling prices. Delaney expects a 3% over-supply of NAND chips in 2015 and 2% oversupply in 2016.

Click here to view Mark Delaney’s rating history and performance.

Zions Bancorporation

Goldman Sachs analyst Ryan Nash upgraded his rating on Zions Bancorporation (NASDAQ:ZION) from Neutral to Buy with a price target of $35, marking a 21.7% potential upside from where the stock last closed. The analyst notes, “We believe ZION is poised for outperformance as we see upside to efficiency expectations in 2016/2017 as 1) liquidity deployment, adding of swaps and fee income growth drive revenue growth, 2) only minimal rate hikes are baked into consensus expectations and provide further upside 3) and it could be an emerging capital return story in 2016 as we estimate at least 260bp of excess capital under next year’s CCAR.”

Click here to view Ryan Nash’s rating history and performance.

WebMD Health Corp.

Cowen & Co analyst Charles Rhyee upgraded his rating on WebMD Health Corp. (NASDAQ:WBMD) from Neutral to Outperform and raised his price target from $42 to $53, representing a 33.1% potential upside from where shares last closed. The analyst notes, “WBMD remains well positioned in its core biopharma advertising business, but we think the more interesting story is its transformation into a broader healthcare service platform, which investors have yet to fully appreciate. As growth inflects in these areas, we think WBMD will see multiple expansion.”

Click here to view Charles Rhyee’s rating history and performance.